HC Wainwright Issues Optimistic Estimate for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW) – Investment analysts at HC Wainwright lifted their Q4 2024 earnings per share (EPS) estimates for Harrow in a research note issued on Tuesday, March 18th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of $0.16 for the quarter, up from their prior forecast of ($0.07). HC Wainwright has a “Buy” rating and a $57.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.21 EPS.

Separately, B. Riley decreased their target price on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th.

Harrow Stock Up 3.0 %

Shares of HROW opened at $28.09 on Friday. Harrow has a 52-week low of $9.86 and a 52-week high of $59.23. The company has a market cap of $1.00 billion, a PE ratio of -29.88 and a beta of 0.69. The business has a fifty day moving average of $29.67 and a 200 day moving average of $38.48. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Hedge Funds Weigh In On Harrow

Institutional investors have recently made changes to their positions in the company. Quest Partners LLC purchased a new position in shares of Harrow during the third quarter valued at $29,000. GF Fund Management CO. LTD. purchased a new position in shares of Harrow during the fourth quarter valued at $25,000. Tower Research Capital LLC TRC increased its stake in shares of Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock valued at $55,000 after buying an additional 1,462 shares during the period. Aquatic Capital Management LLC purchased a new position in shares of Harrow during the fourth quarter valued at $78,000. Finally, AlphaQuest LLC increased its stake in shares of Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock valued at $118,000 after buying an additional 2,889 shares during the period. Hedge funds and other institutional investors own 72.76% of the company’s stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.